Arrhythmogenic Effects of Non Cardiovascular Drugs;Effets Arythmogènes des Médicaments non Cardiovasculaires

Archives des Maladies du Coeur et des Vaisseaux

Volumn 96, Issue SPEC. ISS. 7, 2003, Pages 37-45

  Davy, J M ^a   Raczka, F ^a   Beck, L ^a   Cung, T T ^a   Piot, C ^a   Weissenburger, J ^b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; ASTEMIZOLE; CHLOROQUINE; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; FOSCARNET; HALOFANTRINE; IMIGRANE; IMIPRAMINE; KETOCONAZOLE; METHADONE; MOXIFLOXACIN; NEUROLEPTIC AGENT; NOLAVDEX; PENTAMIDINE; PROBUCOL; RISPERIDONE; SPARFLOXACIN; SULTOPRIDE; TAMOXIFEN; TERFENADINE; UNINDEXED DRUG;

ACTION POTENTIAL; ARRHYTHMOGENESIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; PRESCRIPTION; QT INTERVAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES;

ARRHYTHMIA; HUMANS; RISK ASSESSMENT; TORSADES DE POINTES;

EID: 1542289954     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Cœur 1966; 59: 263-72.
2. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occuring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26.
3. Hollister LE, Kosek JC. Sudden death during treatment with phenothiazine derivatives. JAMA 1965; 192: 93-6.
4. Dargö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J 2001; 3: K70-K80.
5. Weissenburger J, Davy JM. Les torsades de pointe. Encycl Med Chir, 2003 (sous presse).
6. Heverkamp W, Eckardt L, Mönnig G et al. Clinical aspects of ventricular arrhythmias associated with QT prolongation. Eur Heart J 2001; 3: K81-K88.
7. Tzivani D, Keren A, Cohen AM et al. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53: 528-30.
8. Davy JM. Les torsades de pointe médicamenteuses: modes d'initiation. Thèse de doctorot de phormacologie, 1991. Université Paris VI-Pierre et Morie Curie.
9. Antzelevitch C. Heterogeneity of cellular repolarization in LQTS: the role of M cells. Eur Heart J 2001; 3: K2-K16.
10. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long T syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-72.
11. Escande D. Inhibition of repolarizing ionic currents by drugs. Eur Heart J 2001; 3: K17-22.
12. Rasen MR. Isolated tissue models and proarrhythmia. Eur Heart J 2001; 3: K64-K69.
13. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029-34.
14. Donger C, Denjoy I, Berthet M et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96: 2778-81.
15. Schulze-Bahr E, Haverkramp W, Hördt M, Wedekind H, Borggrefe M, Funke H. Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long-QT syndrome. Circulation 1997; 96 (Suppl.): I-210.
16. Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97: 10613-8.
17. Le Heuzey JY, Dayy JM, Weissenburger J et al. et les membres du réseau de recherche clinique INSERM 494012: « Géné tique physiopothologie et diognostic clinique du syndrome du QT long congénital ». Intervale QT et médicoments. Recommandation pour la prescription des médicaments chez les patients atteints du syndrome de QT long. Arch Mal Cœur 1998; 91: 59-66.
18. Haverkamp W, Breithardt G, Camm AJ et al. and the other speakers in the sessions and the choirs of the workshops (see Appendix). The potential for QT prolongation and proarrhythmia by non-antiarrhytmic drugs: clinical and regulatory implications. Eur Heart J 2000; 21: 1216-31.
19. Wysowski DK, Bacsanyi J. Cisapride and fatal orrhythmia (letter). N Engl J Med 1996; 335: 290-1.
20. Walker AM, Szneke P, Weatherby LB et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-62.
21. Simmans FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsade de pointes (letter). Lancet 1998; 2: 264.
22. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989; 298: 325.
23. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. Risk of developping life-threatening ventricular arrhythmia associated with terfenadine in comparison with over the counter histamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 346-52.
24. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. Terfenodine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995; 5: 201-9.
25. Staffa JA, Jones JK, Gable CB, Verspeelt JP, Amery WK. Risk of selected serious cardiac events among new users of antihistamines. Clin Ther 1995; 17: 1062-77.
26. Lindquist M, Edwards IR. Risks of non-sedoting antihistamines (letter). Lancet 1997; 349: 1322.
27. Reilly JO, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc interval abnormalities and psychotic drug therapy in pschiatric patients. Lancet 2000; 355: 1048-52.
28. Sosunov EA, Anyukhovsky EP, Rosen MR. Effects of quinidine on repolarisatian of canine epicardium, mid-myocardium, and endocardium. I: in vitro study. Circulation 1997; 96: 4011-8.
29. Bauman JL. The role of pharmocokinetics, drug interactions and pharmacogenetics in the ocquired Iong QT syndrome. Eur Heort J 2001; 3: K93-K100.
30. Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the evaluation of Medical Products. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, 1997.
31. Sponer G. Prolongation of repolarizatian in pre-clinical investigations and phase I/II clinical trials: what should be done? Eur Heart J 2001; 3: K101-K104.
32. Champeroux P, Martel E, Vannier C et al. The preclinical assessment ot the risk for QT interval prolongation. Therapie 2000; 55: 101-9.
33. Shah R. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fund Clin Pharcol 2002; 16: 147-5
34. Lu HR, Marïen R, Saels A, De Clerck F. Species play an important role in drug-induced prolongation of action potential duration and early after depolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 2001; 12: 93-102.
35. Lacerda AE, Kramer J, Shen KZ, Thomas D and Brown AM. Comparison of block among cloned potassium channels by non-antiarrhytmic drugs. Eur Heart J 2001; 3: K23-K30.
36. Weissenburger J, Davy JM, Chezalviel F et al. Arrhythmogenic activities of antiarrythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther 1991; 259: 871-83.
37. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhytmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 1990; 16: 276-85.
38. Morganroth J. Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J 2001; 3: K105-K111.
39. Redfen WS, Carlsson L, Davis SA et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes or a broad range of drugs: evidence for a provisional safety pargin in drug development. Cardiovas Res 2003; 58: 32-45.